MedPath

Digital Phenotyping for Changes in Activity at the End of Life in People With Dementia

Recruiting
Conditions
Dementia
Registration Number
NCT06032091
Lead Sponsor
University of Bergen
Brief Summary

Background:

Almost 90% of people with dementia develop serious symptoms such as apathy, agitation, pain, and sleep disturbances. Movement and participation in daily activities also decrease dramatically over time. Traditional measures for these symptoms are usually in the form of a questionnaire and are not very accurate. Technology, such as a smartwatch, can be an effective tool for complementing traditional measures. Currently, there are few studies which look at activity and symptom measurements at the end-of-life. This makes results from this study extremely valuable for future care decisions, especially for people which may not be able to communicate their needs during the end-of-life period.

Method/Design:

DIgital PHenotyping in DEMentia (DIPH.DEM), a 3-year cross-sectional observational study (N=50), will look at activities, apathy, agitation, and sleep disturbances using sensing technologies to monitor participants at the end of life. The objective of the study is to use a smartwatch and wireless radar (bedside) device (Somnofy), in addition to validated assessment tools to describe the activity patterns for patients with dementia at the end of life (baseline and every 6.months). We hypothesize that this will enable better estimation of time of death, facilitating discussion surrounding improvement of end-of-life interventions and directives.

Discussion:

The use of sensors (smartwatch and wireless beside device) can provide valuable knowledge on living and dying with dementia, improve end-of-life directives, and provide guidance for timely, appropriate interventions, including referral to palliative services.

Impact on society:

DIPH.DEM has the potential to enable more timely, precise, and quality care for people with dementia living at home, in nursing homes, and hospitals.

Detailed Description

About 90% of people with dementia develop behavioral and psychological symptoms such as agitation, depression and psychosis. In addition, their activity levels decrease over time. Traditional outcome measures can capture physical, mental and social activities of clinical conditions, but usually have low validity. The use of sensor technology in people with dementia is currently poorly validated. DIPH.DEM will examine whether digital tools such as a smartwatch and Somnofy (radar installation) can provide objective measurements of the patient's activities and symptoms throughout the nursing home/hospital stay, including the end of life phase. The participants are people with dementia, \>64 years, who are living in a nursing home. A selection of traditional tools and sensor data is collected at baseline and every 6 months (7 days continuous monitoring). If the participant has a significant change in health status, we will begin with continuous sensor measurements until the end of life (up to 12 weeks). DIPH.DEM can provide valuable information on activity development and symptom presentation toward the end of life in people with dementia. Informal caregivers (usually a family member) will be included to assist with the outcome measures within the study. Participants will be recruited from the Health Region West Norway and Bergen Municipality (sampling method is by invitation to volunteer). All consent procedures will be developed in accordance with Norwegian law.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • People with dementia or who have a likely diagnosis of dementia
  • Hospital (admitted for >3 days)
  • Nursing home resident
  • >64 years old
  • Score of <4 on the 4 A's Test for Delirium (4AT) will be required for inclusion (no delirium)
Exclusion Criteria
  • People without dementia or cognitive impairment
  • People that are considered already in a health status emergency (< 6 weeks to live)
  • People that are not living in the nursing home

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Activities of Daily Living (ADL) - Physical Self Maintenance Scale (PSMS), Lawton and Brody, 1969.Baseline and every 6.months (up to one year)

Personal functional daily activities such as toileting, eating, self-care, movement/ambulation, transfers, bathing. 6 sections - scoring 1-5 on each, higher score indicates greater disability.

Digital biomarker estimations for apathy, agitation, pain, and sleep disturbancesBaseline and every 6.months (up to one year), continuous up to 12 weeks if a serious health event occurs

Estimation of activity changes and selected behavioral disturbances resulting from the combined digital phenotype modeling; these estimations are experimental and "scores" will be based on analysis of found data after data collection period.

Secondary Outcome Measures
NameTimeMethod
InterRai-Palliative Care (InterRai-PC)Baseline and every 6.months (up to one year)

Oral health section only/specific of the InterRai-PC, assessment of symptoms

Mobilization, Observation, Behavioral, Intensity Dementia (MOBID-2)Baseline and every 6.months (up to one year)

Measurement of pain specific to a dementia population; visual analog scale alongside likert scale 0-10, 0 being no pain and 10 being the worst pain, validated with persons with dementia

Digital secondary outcomesBaseline and every 6.months (up to one year)

Device-native scores for activity and sleep.

Neuropsychiatric Inventory - Nursing Home Version (NPI-NH)Baseline and every 6.months (up to one year)

Validated in Norwegian nursing homes, measuring symptoms of behavioral and psychological symptoms of dementia (BPSD) such as: apathy, agitation, depression, anxiety, sleep disturbance, and appetite/eating. Gives scores 1-4 (higher numbers being daily occurance) for amount, 1-3 for intensity and burden of care related to symptom for caregiver (1-5) for each symptom.

Edmonton Symptom Assessment System (ESAS++)Baseline and every 6.months (up to one year)

Symptom assessment for palliative care period and the end of life period, with added items: death rattle, dyspnea, sleep disturbances, emesis specific to end of life. Likert scale 0-10; 0 indicating no symptoms and 10 is worst symptom.

Trial Locations

Locations (1)

Bergen Røde Kors Sykehjem AS

🇳🇴

Bergen, Vestland, Norway

Bergen Røde Kors Sykehjem AS
🇳🇴Bergen, Vestland, Norway
Morten Amundsen
Contact
+4755397700
postmottak@brks.no
© Copyright 2025. All Rights Reserved by MedPath